Abstract
Cataracts are a major cause of blindness and it is due to protein aggregation in the eye lens that is accelerated by aldose reductase (AR)-induced sorbitol accumulation. Therefore, it is of interest to evaluate the anti-cataract potential of six phytochemicals from Siddha medicinal herbs (carinol, voacangine, berberine, piperine, sesamin and isoamericanin A) using molecular docking analysis with human aldose reductase (PDB ID: 4GCA) where epalrestat is used as the standard compound. Analysis shows that berberine, piperine, sesamin and carinol have optimal binding interactions with aldose reductase, performing similar to the standard drug epalrestat having estimated free energy values of -10.37 kcal/mol and -10.13 kcal/mol, respectively for further consideration. Thus, the traditional use of these herbs in Siddha medicine as a potential, affordable and non-surgical cataract-preventative agent is shown.
Keywords: Cataract, kan noigal, siddha medicine, eye diseases, epalrestat
Background:
Cataracts, characterized by the clouding of the eye's lens, are a leading cause of vision loss and blindness, primarily caused by aging but also by factors such as congenital conditions, eye injuries, inflammation and diseases like glaucoma and diabetes. Cataract development is also associated with steroid use and certain radiation exposures. As global life expectancy increases, the prevalence of cataracts may raise, which leads to 2.2 billion individuals with vision impairment, among that one billion cases are either untreated or preventable globally. World Health Organisation (WHO) estimates that 36% of distance vision impairment and 17% of cataract-related vision impairment only receive an appropriate intervention in global population. Despite that, the cataracts can be curable by surgery but also unattainable in many nations [1, 2]. In India, Cataract remains the major cause of blindness (66.25%) and visual impairment (71.25%) in individual's age around 50 and older, even though with the high cataract surgical coverage rate (93.2%). Due to the unique benefits of modern intraocular lenses with advanced materials and optical properties, surgery has become the primary treatment for cataracts. However, surgery has the complications, like incision infections, posterior capsular rupture, capsular contraction syndrome, intraocular lens dislocation and dry eyes [5]. Research studies revealed that uncontrolled systemic health conditions, financial difficulties, lack of perceived need for surgery and fear in surgical procedures are the barriers that inhibit the elderly and rural populations for undergo cataract surgery [4]. The out of pocket expenses for pediatric cataract surgery in one eye ranged from Rs. 4,722 ($122) to Rs. 18,537 ($475), that reduces the treatment accessibility among public in developing nations [3, 5]. Since the cataract is unpreventable, but its development may delayed by reducing cigarette smoking, alcohol consumption and exposure of ultraviolet light. Therefore, it needs to explore medications for the prevention and treatment of cataract is of great importance. In Siddha system of medicine Akattiyar Nayana Viti and Nakamuni Nayana Viti precisely mentioned eye diseases under 96 types of Kan noikal along with therapeutic management and lifestyle modifications. Jeyavenkatesh et al. provided an in-depth analysis and clinical correlation of Kan noikal (eye diseases) with modern diagnostic perspectives. They distinctly identified and described conditions such as Neeraezhu kaasam (Retinal cataract), Neela kaasam (Blue opaque cataract), Kumari kaasam (Chronic cataract), Paravai Poo (Opaque crystal cataract), Silettuma kaasam (White cataract) and Pittha kaasam (Yellow cataract). The treatment modalities are categorized into Deva Maruthuvam, Maanidar Maruthuvam and Asura Maruthuvam based on the disease's signs and symptoms, severity and prognosis.
In Deva Maruthuvam and Maanidar Maruthuvam, therapies such as herbal extracts, ghee-based collyriums, oil baths, poultices and fomentations - often incorporating mineralo-metallic ingredients - are extensively employed. In contrast, Asura Maruthuvam involves surgical interventions, including excision, pricking, peeling, venesection, leech therapy and cauterization. These procedures utilize specialized instruments such as Vilisam, Pulladi, Kakkai Kaal, Piruma, Anjanak Koel and Kariak Koel. Additionally, the pre- and post-operative protocols, along with medications specific to surgical procedures, are meticulously detailed in Akattiyar Nayana Viti. Cataract, being one such condition, has been comprehensively addressed within it [6, 7]. Cataracts involve lens clouding caused by protein and fiber changes, with osmotic expansion that accelerates the disease progression. Aldose reductase, an enzyme implicated in cataract development, converts glucose to sorbitol, leading to its accumulation in lens cells and causing osmotic stress and damage; inhibiting this enzyme may prevent or delay cataract formation. Epalrestat, a renowned aldose reductase inhibitor, was selected as standard to evaluate the efficacy of the herbal samples [8]. Binding of phytocomponents with the core amino acids (Trp20, Val47, Tyr48, Trp79, His110, Trp111, Thr113, Phe122, Gln183, Tyr209, Ala299 and Leu300.) of the target by forming hydrogen bond will inhibit the activity of the enzyme aldose reductase, thereby will delay sorbitol accumulation and contributes to delayed cataract development. Carissa spinarum, Tabernaemontana divaricata, Coptis teeta, Piper longum and Trianthema decandra are among the Siddha medicinal herbs exclusively mentioned for their use in treating eye diseases, with potential anti-cataract properties [9]. Therefore, it is of interest to explore their anti-cataract efficacy by evaluating their ability to inhibit aldose reductase activity so as to delay the progression of cataracts.
Materials and Methods:
Study drug:
The study evaluated six phytochemicals derived from medicinal herbs traditionally used in Siddha medicine for eye diseases, such as Carinol from Carissa spinarum, Voacangine from Tabernaemontana divaricata, Berberine from Coptis teeta, Piperine and Sesamin from Piper longum and Isoamericanin A from Trianthema decandra that are detailed in Table 1. Additionally, Epalrestat was used as a standard drug.
Table 1. Medicinal herbs and their selected phytocomponents for docking.
| S. No | Medicinal herbs | Indication as per Siddha literature | Phytochemicals | |
| Botanical Name | Vernacular Name | |||
| 1. | Carissa spinarum | Cirukalapu | Cataract, Corneal opacity, Crushed water drops applied before sunrise, to relieve symptoms of eye diseases. | Carinol [10] |
| 2. | Tabernaemontana divaricate | Nantiyavattampu | Cataract, Diseases of pupil. | Voacangine [11] |
| 3. | Coptis teeta | Pitarokini | Cataract, Diseases of eyelid, Decoctions for eye wash helps to cleanse and prevent Eye diseases, Root powder - Oil bath used to prevent eye diseases. | Berberine [12] |
| 4. | Piper longum | Tippili | Helps to prevent eye disease. | Piperine [13], Sesamin [13] |
| 5. | Trianthema decandra | Caranaiver | 96 types of Eye diseases. | Isoamericanin A [14] |
Target protein preparation:
The target protein, Human Aldose Reductase (PDB ID: 4GCA), was retrieved from the Protein Data Bank and prepared for docking by removing water molecules, ligands and non-essential heteroatoms, followed by energy minimization to optimize the structure [15]. Key active site residues associated with cataract formation - Trp20, Val47, Tyr48, Trp79 and His110 were identified as primary binding sites for ligand interactions. The 3D crystal structure of the target protein is shown in Figure 1 (see PDF).
Ligand preparation:
Each selected phytochemical was prepared for docking by obtaining its 2D and 3D structures from databases or molecular modelling software, followed by energy minimization to ensure stable conformations and reduced steric hindrance. Each ligand was then parameterized with appropriate partial charges and rotatable bonds to enable flexible interactions with the target protein. The structured of ligands are shown in Figure 2 (see PDF) and their properties were tabulated in Table 2.
Table 2. Ligand properties of the compounds selected for docking analysis.
| Compound | Molar weight g/mol | Molecular Formula | H Bond Donor | H Bond Acceptor | Rotatable bonds |
| Carinol | 618.8 g/mol | C39H42N2O5 | 5 | 5 | 12 |
| Voacangine | 368.5 g/mol | C22H28N2O3 | 1 | 4 | 4 |
| Berberine | 336.4 g/mol | C20H18NO4 | 3 | 0 | 4 |
| Piperine | 285.34 g/mol | C17H19NO3 | 0 | 3 | 3 |
| Sesamin | 354.4 g/mol | C20H18O6 | 0 | 6 | 2 |
| Isoamericanin A | 328.3 g/mol | C18H16O6 | 3 | 6 | 4 |
| Epalrestat | 319.4 g/mol | C15H13NO3S2 | 1 | 5 | 4 |
Docking procedure:
Docking simulations were conducted using AutoDock tools to evaluate the binding interactions between the target protein and each ligand. A grid box was centered on key active site residues to confine docking to relevant regions. Parameters, including binding affinity (ΔG), inhibition constant (Ki) and interaction surface, were calculated for each ligand [16, 17]. The binding interactions and energy values were then analyzed and compared with those of Epalrestat to determine the relative binding efficacy of each compound.
Results:
The molecular interactions showed that compounds like berberine, piperine, sesamin and carinol exhibited 8 to 10 viable interactions with the residual amino acid present in the target aldose reductase enzyme whereas Epalrestat showed 8 interactions. Carinol exhibited the strongest binding affinity with an estimated energy of -10.13 kcal/mol and an inhibition constant (Ki) of 37.38 nM, showing 10 key interactions with Trp20 and His110. Sesamin followed closely with a binding energy of -10.37 kcal/mol and a Ki of 25.25 nM, indicating its effectiveness with 8 interactions. Piperine and Berberine also showed good binding profiles, both with 8 interactions, while Voacangine and Isoamericanin A had less interaction. Notable amino acids involved included Trp20, Val47 and Tyr48, which play essential roles in the enzyme's activity. The summary of the molecular docking studies of Phytochemicals against Human Aldose reductase enzyme (PDB) - 4GCA are tabulated in Table 3 and Amino acid Residue Interaction of Lead against Human Aldose reductase enzyme (PDB) - 4GCA are outlined in Table 4. Likewise the Docking poses of phytochemicals with Human Aldose reductase enzyme, 2D interaction plot analysis of Phytochemicals and the Hydrogen bond plotting with core amino acid Analysis of Phytochemicals are depicted in Figure 3 (see PDF), Figure 4 (see PDF) and Figure 5 (see PDF).
Table 3. Summary of the molecular docking studies of phytochemicals against human aldose reductase enzyme (PDB) - 4GCA.
| Compound | Est. Free Energy of Binding | Est. Inhibition Constant, Ki | Electrostatic Energy | Total Intermolecular Energy | Interact. Surface |
| Carinol | -10.13 kcal/mol | 37.38 nM | -0.03 kcal/mol | -11.44 kcal/mol | 852.146 |
| Voacangine | -8.31 kcal/mol | 808.26 nM | -0.07 kcal/mol | -9.00 kcal/mol | 787.447 |
| Berberine | -8.87 kcal/mol | 317.26 nM | -0.11 kcal/mol | -9.36 kcal/mol | 737.756 |
| Piperine | -9.96 kcal/mol | 49.94 nM | -0.01 kcal/mol | -10.47 kcal/mol | 715.148 |
| Sesamin | -10.37 kcal/mol | 25.25 nM | -0.04 kcal/mol | -10.91 kcal/mol | 839.454 |
| Isoamericanin A | -9.02 kcal/mol | 244.57 nM | -0.11 kcal/mol | -9.30 kcal/mol | 759.975 |
| Epalrestat | -9.90 kcal/mol | 55.17 nM | -0.85 kcal/mol | -11.24 kcal/mol | 725.143 |
Table 4. Amino acid residue interaction of lead against human aldose reductase enzyme (PDB) - 4GCA.
| Compounds | Interaction | Amino Acid Residues | ||||||||||||||||||
| Carinol | 10 | 20 | 48 | 77 | 110 | 111 | 113 | 115 | 122 | 159 | 160 | 183 | 209 | 219 | 298 | 299 | 300 | 303 | 309 | 311 |
| TRP | TYR | LYS | HIS | TRP | THR | PHE | PHE | SER | ASN | GLN | TYR | TRP | CYS | ALA | LEU | CYS | TYR | PHE | ||
| Voacangine | 6 | 20 | 47 | 48 | 49 | 111 | 121 | 122 | 219 | 300 | ||||||||||
| TRP | VAL | TYR | GLN | TRP | PHE | PHE | TRP | LEU | ||||||||||||
| Berberine | 8 | 20 | 47 | 79 | 111 | 113 | 115 | 122 | 219 | 299 | 300 | 303 | 309 | 310 | 311 | |||||
| TRP | VAL | TRP | TRP | THR | PHE | PHE | TRP | ALA | LEU | CYS | TYR | PRO | PHE | |||||||
| Piperine | 8 | 20 | 48 | 79 | 110 | 111 | 113 | 115 | 122 | 219 | 298 | 300 | 303 | 309 | ||||||
| TRP | TYR | TRP | HIS | TRP | THR | PHE | PHE | TRP | CYS | LEU | CYS | TYR | ||||||||
| Sesamin | 8 | 20 | 43 | 48 | 110 | 111 | 122 | 160 | 183 | 209 | 210 | 219 | 260 | 262 | 298 | 300 | ||||
| TRP | ASP | TYR | HIS | TRP | PHE | ASN | GLN | TYR | SER | TRP | ILE | LYS | CYS | LEU | ||||||
| Isoamericanin A | 5 | 20 | 47 | 48 | 49 | 111 | 121 | 122 | 219 | 300 | 303 | 309 | ||||||||
| TRP | VAL | TYR | GLN | TRP | PHE | PHE | TRP | LEU | CYS | TYR | ||||||||||
| Epalrestat (Standard drug) | 8 | 20 TRP | 47 VAL | 48 TYR | 79 TRP | 111 TRP | 113 THR | 115 PHE | 122 PHE | 219 TRP | 300 LEU | 303 CYS |
Discussion:
Molecular docking is a computational tool used to predict the binding potential of small molecules, such as phytochemicals from medicinal plants, to specific targets like enzymes. In this study, bioactive compounds including Carinol, Voacangine, Berberine, Piperine, Sesamin and Isoamericanin A were selected from Carissa spinarum, Tabernaemontana divaricata, Coptis teeta, Piper longum and Trianthema decandra, respectively, to evaluate their In-silico aldose reductase inhibition activity. The results revealed that Berberine, Piperine, Sesamin and Carinol demonstrated strong binding interactions with the core amino acids of aldose reductase, performing either on par with or better than the standard drug Epalrestat. Among these, Sesamin exhibited the highest binding affinity, with a calculated free energy of binding of-10.37 kcal/mol, surpassing Epalrestat's-9.90 kcal/mol, suggesting greater potential effectiveness in preventing cataract formation. This strong binding is further reinforced by Sesamin's anti-inflammatory and antioxidant properties that help to reduce oxidative stress a major factor in cataractogenesis and promote overall lens health [21].
The multiple role of Sesamin as an aldose reductase inhibitor and antioxidant may offer a protective effect against cataracts, particularly in populations vulnerable to oxidative stress, such as the elderly and diabetics. Furthermore, Berberine, Piperine and Carinol are phytochemicals with promising anti-cataract potential, primarily attributed to their antioxidant [10, 18, 19], anti-inflammatory [10, 18, 20] and aldose reductase inhibitory properties [18, 19, 22]. These compounds help protect the lens from oxidative stress, a key contributor to cataract formation. Additionally, by inhibiting the enzyme aldose reductase, they prevent the accumulation of sorbitol in the lens, a mechanism particularly crucial in managing diabetic cataracts. Research studies have revealed that the methanolic extract of Piper longum Linn effectively neutralizes free radicals, thereby preventing lens opacification [2323]. Trianthema decandra has traditionally been used to treat conditions such as corneal ulcers, night blindness and bacterial infections. Its methanolic extract (METD) has shown anti-cataract potential by maintaining GSH levels and mitigating oxidative stress [24]. Coptis teeta, which contains berberine, exhibits antioxidant, -inflammatory and anti-trachoma properties [25]. Meanwhile, Tabernaemontana divaricata protects against selenite-induced cataractogenesis by preserving lenticular GSH, maintaining calcium homeostasis and safeguarding lens proteins from proteolysis [26]. Collectively, these plants demonstrate significant therapeutic potential for cataract prevention through their antioxidant and anti-inflammatory properties.
Multitudinous scientific studies explore the efficacy of medical plants in the context of cataract prevention by inhibiting aldose reductase and free radical scavenging. Gacche and Dhole and Upadhyaya et al. highlighted the anti-cataract activity of Terminalia arjuna Upadhyaya, Aegle marmelos, Withania somnifera, Boswellia serrata, Moringa oleifera, Tinospora cordifolia, Azadirachta indica, Emblica officinalis, Terminalia bellirica, Terminalia chebula, Curcuma longa and Camellia sinensis by their aldose reductase inhibition and oxidative stress inhibitory activity [27, 28]. Ji et al. exhibited the in-vivo aldose reductase inhibition activity of diosgenin an active moiety of Dioscorea villosa in a galactosemic rat model, underscoring its potential as an anti-cataract agent [8]. Collectively, these studies emphasize the significate role of medicinal herbs in cataract management. According to Siddha principles, cataract is a pathological condition resulting from vitiated Iyam and primarily occurs during Iya kaalam (the geriatric age group). The herbs recommended for treating cataracts, which are predominantly bitter in taste, have the ability to reduce vitiated Iyam and prevent cataract progression due to their anti-cataract, antioxidant and anti-inflammatory properties. These properties, reinforced by molecular docking studies, indicate that compounds in this study have the potential to delay cataract progression and may serve as promising non-surgical treatments for cataracts. As a result, the utilization of these phytocompounds could provide a non-invasive and cost-effective alternative or complement to cataract surgery, particularly in resource-constrained settings where access to surgical interventions is limited.
Implications for future research:
This study emphasizes the need for extensive in-vitro and in-vivo research, along with clinical trials, to validate the efficacy and safety of these phytochemicals. While Tabernaemontana divaricata and Trianthema decandra are traditionally used to treat various eye conditions, the active components Voacangine and Isoamericanin A identified in this study showed limited efficacy compared to the standard. Further research is essential to explore and evaluate other bioactive compounds from these plants for their potential anti-cataract properties. Additionally, future studies should investigate synergistic interactions to enhance therapeutic effects, assess bioavailability and toxicity and determine their feasibility as alternative or complementary treatments for cataracts.
Conclusion:
The molecular docking analysis of phytochemicals derived from Siddha medicinal herbs showed optimal binding interactions with aldose reductase, suggesting promising anti-cataract activity. The high binding affinities of compounds such as sesamin and carinol suggest their potential as non-surgical, preventive solutions for cataract development, particularly in high-risk populations. This study not only validates the traditional use of these herbs in Siddha medicine but also highlights their phytochemicals as promising prospects for further pharmacological research in cataract prevention.
Ethical approval:
The authors declare that due to an In-silico analysis this study does not need any ethical approval.
Consent to participate:
Not applicable
Consent to publish:
Not applicable
Author contributions:
All authors have equally contributed in the manuscript preparation like concept, designing and collection of the data, as well as the writing and revision of the article.
Funding:
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Availability of data and materials:
All the data's are available with authors upon reasonable request
Source of funding:
No funds, grants, or other support was received for this work.
Acknowledgments
The authors express their sincere thanks to Prof. Dr. N. J. Muthukumar, Director General, Central Council for Research in Siddha, Ministry of Ayush, GoI, Chennai and Dr. P. Sathiyarajeswaran, Assistant director (Siddha) S-IV i/c, Siddha Regional Research Institute, Puducherry for extending their support and encouragement.
The authors have no relevant financial or non-financial interests to disclose.
Edited by P Kangueane
Citation: Ramamoorthy et al. Bioinformation 21(3):559-566(2025)
Declaration on Publication Ethics: The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.
Declaration on official E-mail: The corresponding author declares that official e-mail from their institution is not available for all authors.
License statement: This is an Open Access article which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License
Comments from readers: Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.
Bioinformation Impact Factor:Impact Factor (Clarivate Inc 2023 release) for BIOINFORMATION is 1.9 with 2,198 citations from 2020 to 2022 taken for IF calculations.
Disclaimer:The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required. Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain.
References
- 1.WHO Regional Office for the Eastern Mediterranean. World Health Organization. 2024.
- 2. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment .
- 3.Gogate P, et al. International journal of ophthalmology. . 2010;3:182. doi: 10.3980/j.issn.2222-3959.2010.02.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Shambhu R, et al. Indian journal of community medicine. . 2022;47:116. doi: 10.4103/ijcm.ijcm_783_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Liu X-Y, et al. Evidence-based complementary and alternative medicine. . 2022;2022:7776403. doi: 10.1155/2022/7776403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Jeyavenkatesh J, et al. Asian Journal of Research and Reports in Ophthalmology. . 2022;5:19. [Google Scholar]
- 7. https://siddhacouncil.com/ccrs/wp-content/uploads/2020/08/Siddha-Dossier_CCRS_Chennai-1.pdf .
- 8.Ji L, et al. Journal of diabetes research. . 2017;2017:7309816. doi: 10.1155/2017/7309816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Utthamarayan K.S. Indian Medicine and Homoeopathy Department. 6th edition. Chennai: Siddhar Aruvai Maruthuvam.; 2013. [Google Scholar]
- 10.Sharma N, et al. Separations. . 2023;10:158. doi: 10.3390/separations10030158. [DOI] [Google Scholar]
- 11.Naidoo C.M, et al. Plants. . 2021;10:313. doi: 10.3390/plants10020313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Behl T, et al. Molecules. . 2022;27:5851. [Google Scholar]
- 13.Tiwari A, et al. Medicine in Drug Discovery. . 2020;7:100027. doi: 10.1016/j.medidd.2020.100027. [DOI] [Google Scholar]
- 14.Rajarathinam G, et al. International Journal of Engineering Science and Technology. . 2010;2:976. [Google Scholar]
- 15.Bikadi Z, et al. J Cheminform. . 2009;1:15. doi: 10.1186/1758-2946-1-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Morris G.M, et al. J Comput Chem. . 1999;19:1639. [Google Scholar]
- 17.Solis F.J, Wets R.J. Math Oper Res. 1981;6:19. [Google Scholar]
- 18.Yin J, et al. Acta Pharmaceutica Sinica B. . 2012;2:327. doi: 10.1016/j.apsb.2012.06.003.. [DOI] [Google Scholar]
- 19.Kumar S, et al. Expert Opin Pharmacother. . 2013;14:1723. doi: 10.1517/14656566.2013.815725. [DOI] [PubMed] [Google Scholar]
- 20.Wang Y, et al. J Med Food. . 2023;26:693. [Google Scholar]
- 21.Alshahrani S, et al. Int J Mol Sci. . 2022;23:11615. [Google Scholar]
- 22.Julius A, Hopper W. J Young Pharm. . 2018;10:62. doi: 10.5530/jyp.2018.10.15. [DOI] [Google Scholar]
- 23.Rathore S.S, et al. International Journal of Multidisciplinary Educational Research. . 2021;10:137. [Google Scholar]
- 24.Mihir Y.P, et al. JOJ Ophthal. . 2019;7:555715. doi: 10.19080/JOJO.2019.07.555715. [DOI] [Google Scholar]
- 25.Nafees S, et al. Avicenna J Phytomed. . 2022;12:566. doi: 10.22038/AJP.2022.20345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Anbukkarasi M, et al. Biocatalysis and Agricultural Biotechnology. . 2020;23:101475. doi: 10.1016/j.bcab.2019.101475. [DOI] [Google Scholar]
- 27.Gacche R.N, Dhole N.A. Food Chem Toxicol. . 2011;49:1806. doi: 10.1016/j.fct.2011.04.032. [DOI] [PubMed] [Google Scholar]
- 28.Upadhyaya S.R, et al. Journal of Chemistry. . 2023;2023:9614164. doi: 10.1155/2023/9614164. [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All the data's are available with authors upon reasonable request
